Life Sciences Archive » October, 2025

Life Sciences - October, 2025

304 articles

• Pfizer Sues Metsera, Novo Nordisk Over $9B Buyout 'Bribe'
• Alaska Joins Utah In Firing Motley Rice From Opioid Case
• Drugmakers Can't End States' Dermatology Price-Fixing Suits
• Amgen Again Challenges Colo. Price Cap For Arthritis Drug
• Ga. Panel Says McClain Standard Applies In Sterigenics Case
• Wheeling & Appealing: The Latest Must-Know Appellate Action
• Monthly Merger Review Snapshot
• Hawaii Judge Declares FDA's Mifepristone Regs Unlawful
• Gov't Owes $330K In Fees For NSF Funding Fight, Court Told
• FDA Warns Against Fluoride Use In Young Children
• What's New In FDA's Latest Cell And Gene Therapy Guidance
• Bayer Investors Get Final OK For $38M Settlement, Atty Fees
• Trending At The PTAB: A Potential Barrier To Serial Challenges
• Squires Vows To Open USPTO Doors To AI Technologies
• Obesity Drugmaker Escapes Clinical Trial Securities Suit
• 3 Argument Sessions Benefits Attys Should Watch In Nov.
• What's Changing For Cos. In New Calif. Hazardous Waste Plan
• Industry Groups Seek More Time To Comment On PTAB Rules
• 3rd Circ. Preview: BMW, MiLB And Sandoz Top Nov. Lineup
• Philly Accuses PBMs Of Knowingly Enabling Opioid Crisis
• Med Robot Co. Tells 9th Circ. Not To Revive 'Disfavored' Suit
• Fiber Optics Co. Agrees To Reforms To End Derivative Suit
• Avantor Minimized Competition On Lab Biz, Investor Says
• Fed. Circ. Explains Rule While Upholding Merck PTAB Loss
• 2nd Ex-Magellan Exec Avoids Jail Over Faulty Lead Tests
• Lawmakers Slam Value-Based Patent Fee Proposal
• J&J's Janssen Says 3rd Circ. Should Reverse $1.6B FCA Win
• Generic-Drug Firms Want To Fast-Track Conn. Price Cap Fight
• Fed. Circ. In September: The Printed Matter Doctrine Expands
• McCarter & English Used Doctrine As 'Whipsaw,' Panel Hears
• Justices' LabCorp Punt Leaves Deeper Class Cert. Circuit Split
• Mich. Top Court Upholds Gilead Immunity In COVID Drug Case
• Judge Unpauses 'Important' Suit Over Vax Guidelines
• Novo Nordisk Bids $9B For Metsera, Jeopardizing Pfizer Deal
• Practicing Stoicism Makes Me A Better Lawyer
• DOJ Subpoena Called 'Pressure' To Ax Gender-Affirming Care
• DexCom Misled Investors About Its Diabetes Tech, Suit Says
• Conn. Med Spa Says Ex-Workers Poaching Clients, Employees
• Where PTAB Institution Reviews Stand As Squires Takes Lead
• Taro Pharma Beats Investor Suit Over $43-Per-Share Buyout
• Ga. Panel Backs Sanctions For 'Delaying Tactic' In Pot Dispute
• Broader Eligibility For AI-Related Patents May Be Coming
• FDA Unveils Plan To Speed Biosimilar Drugs To Market
• 3 Pharmaceutical Firms Will Pay $4M To Tribes In Opioid MDL
• The Biz Court Digest: Texas, One Year In
• AI Product Safety Insights May Expand Foreseeability
• Brothers Found Guilty Of $100M HIV Drug Fraud
• Law School's Missed Lessons: Educating Your Community
• Organ Transplant System Reforms Mark Regulatory Overhaul
• PE-Backed Medical Supplies Giant Medline Files For IPO
• 'Smart Drugs' Amphetamine Suit Moves Forward Minus Execs
• 3 Firms Guide Thermo Fisher On $8.9B Clario Deal
• Off-Label Prescribing Was Common, Novo Nordisk Tells Jury
• Apple Spared From Some Masimo Patent Claims Before Trial
• Perceptive Asks Chancery To Block Kindbody Ex-CEO's NY Suit
• Trump Admin Ordered To Halt Some Shutdown-Linked Layoffs
• Bias Claims From Worker Who Failed Drug Test Can Proceed
• Activists Drop Challenge To FDA Inaction On Menthol Cigs
• J&J Hit With $20M Verdict In Fla. Talc Trial
• Adapting To USPTO's Reduction Of Examiner Interview Time
• Federal Grantees May Soon Face More Limitations On Speech
• Exactech Gets Another $19M In DIP Funds Ahead Of Sale
• Ex-Philips CEO Can't Undo Finding He Misled Shareholders
• Akin Beats Malpractice Claim Over Alleged IP Theft Plot
• 4th Circ. Overturns Landmark W.Va. Opioid Verdict
• Greenberg Traurig Adds Faegre Drinker Mass Tort Pro In NJ
• 5 Crisis Lawyering Skills For An Age Of Uncertainty
• Texas Accuses Tylenol Makers Of Hiding Autism Danger
• Whistleblower 'Horrified' By Novo Nordisk Drug Sales Tactics
• Bros. Had No Fraud Intent In HIV Drug Scam, Fla. Jury Told
• Teva To Pay $35M In Suit Over Delayed Generic Inhalers
• Acadia Pushes For Appeal Of Investors' Partial Early Win
• LifeScan Gets Final OK On Ch. 11 Plan After Deal With PBMs
• Feds Fight Union Bid To Protect Jobs During Gov't Shutdown
• Fed. Circ. Won't Revive Heart Valve IP Suit Against Edwards
• AbbVie Defends Challenge Of Colorado's Discount Drug Law
• Anticipating FTC's Shift On Unfair Competition Enforcement
• Judge Tosses Eli Lilly Suit Over Telehealth Weight Loss Drugs
• Samsung Infringed Smart Ring IP, Suit Says
• Moderna Says Vax Efficacy Math Doesn't Show Investor Fraud
• Insights From Recent Cases On Navigating Snap Removal
• Biotech Firm MapLight Inks $251M IPO Amid Shutdown
• Catching Up With Delaware's Chancery Court
• Ex-Magellan CEO Avoids Prison Over Faulty Lead Tests
• It's Time For The Judiciary To Fix Its Cybersecurity Problem
• Covington Helps Novartis Buy Avidity Biosciences For $12B
• Pfizer Hit With More Suits Over Depo-Provera
• Ohio, Ky. Reps Again Pursue Bill To Make PTAB Optional
• GNC Franchisee Cos. Largely Lose Bid To Toss Award Order
• USPTO Chief To Review PTAB Ruling On Tire Sensor Patent
• Tricida Investors Win OK Of $14.2M Deal Over Kidney Drug
• Generic-Drug Makers Want Conn. Price Cap Blocked During Suit
• Eli Lilly Buying Eye Disease Biotech For Up To $262M
• Abbott Wins Third Bellwether In Cow Milk Baby Formula MDL
• Taxation With Representation: Latham, Wachtell, Gibson Dunn
• NY AG Sues Vape Shop Owners For Selling To Kids
• Ky. Rep. Revives Attempt To Abolish PTAB, Expand Eligibility
• Chancery Maps Out Math For Hefty Drug Co. Breach Interest
• Investor Says Biotech Co. Rigged Votes To Expand Share Pool
• RingConn Settles With Oura After ITC Import Ban
• Freshly Launched Legal Org. Plans To Protect Abortion Docs
• Bayer Wants Full Fed. Circ. Scrutiny Of Axed Xarelto Claims
• SEC Being Misled In CBD Fraud Fight, CEO Claims
• Ex-Exec Accused Of Stealing IVF Co.'s Trade Secrets
• Eli Lilly Says Pharmacy Mass-Producing Weight Loss Drug
• Avadel, Jazz Settle Sleep Disorder Drug Claims
• Del. Startup Accuses Ex-CEO In Chancery Of Stock Scheme
• Feds, Ex-Magellan CEO Still Split Over Sentencing Factors
• Buyers Sue Colgate Over Lead Found In Kids' Toothpaste
• 5th Circ. Revives Religious Bias Suit Over DOD Vaccine Policy
• Writing Novels Makes Me A Better Lawyer
• Novo Nordisk Paid Patient Benefits, Not Bribes, Jury Hears
• Judge Voids HHS Rule Banning Gender Identity Discrimination
• Bristol-Myers $450M Payment Dispute Heads To Arbitration
• Judge Tosses Ingenus Suit Over Leukemia Treatment Patent
• Purdue Fights Baltimore Objection Ahead Of Ch. 11 Plan Trial
• Latham Adds BCLP Environmental Atty In SF Bay Area
• Unions Pursue More Protection For Federal Workers In Shutdown
• SDNY OpenAI Order Clarifies Preservation Standards For AI
• What 9th Circ.'s Rosenwald Ruling Means For Class Actions
• Trump Flouted Clean Air Act With Rule Delay, Enviro Orgs. Say
• 5 Firms Guide $2.1B Alkermes-Avadel Sleep Medicine Deal
• NC Biz Court Bulletin: COVID Coverage, A Suspect Signature
• Naked Whey Sued Over Reports Of Lead In Protein Powder
• Novo Nordisk Says Officials Not Qualified To Doubt Drug Bills
• Patent Landscape Shifts As Squires Takes On Key PTAB Role
• Judge Trims Pharma Co. Claims Against Ex-Employees
• 3rd Circ. Reinstates Union Rep's Pharmacy Fraud Charges
• 10x Genomics Hits Illumina With 2 Gene Tech Patent Suits
• Nexus Can't Pursue IP Dropped Before Trial, Del. Judge Says
• Regeneron, Rival End Patent Fight Over Eye Med Biosimilar
• Investors Tell Chancery CytoDyn Board Ignored Drug Scheme
• J&J Unit Seeks Sanctions Over Doc's Deleted Talc Emails
• Full Fed. Circ. Won't Rehear $125M Medtronic Patent Verdict
• Trends In Post-Grant Practice Since USPTO Denial Guidance
• J&J Appeals $25M Loss In Conn. Builder's Asbestos Case
• PE Giants Ink $18.3B Deal For Hologic Amid Megadeal Blitz
• Novartis Says Alexion's 'Block The Cause' Ads Are False
• Novo Nordisk Trial Kicks Off Over Kickback Allegations
• Drugmakers Say Conn. Law Illegally Extends Beyond State
• Biotech Co. Asks SEC For Emergency Delisting Pause
• Sterigenics Nears Win In Georgia Ethylene Oxide Litigation
• Tylenol Maker Tells FDA Not To Add Autism Warning
• Ex-GC Says Honeywell Can't Boot Her Age Bias Suit To China
• More Fed. Workers Added To TRO Blocking Shutdown Layoffs
• Catching Up With Delaware's Chancery Court
• Top Court Won't Hear Chicago Hospital's Medicaid Dispute
• High Court Won't Hear Hospital Vax Mandate Case
• Justices Won't Review Merck's Immunity From Vaccine Claims
• USPTO Under Squires: A Look At The First Month
• Jury Clears Disney Unit Of Bias In '9-1-1' Actor's Vax Firing
• Settlement Balk Jeopardizes $32M Class Deal In Chancery
• Mixed Discretionary Denial Batch Caps Off Big Week For PTAB
• Insys Ex-CEO Babich Agrees To $30M Trustee Deal In Del.
• NJ Parents Keep Fighting State Over Storage Of Babies' DNA
• 3rd Circ. Says No Duty To Inform Criminal Clients Of Liability
• Expert Reports Can't Replace Facts In Securities Fraud Cases
• Federal Courts To Scale Back Operations Amid Shutdown
• Boston Scientific Buying Rest Of Pain Therapy Biz For $533M
• USPTO Head To Take Over Patent Review Institution Decisions
• Utah Fires Motley Rice From Opioid Case
• DaVita, Fresenius Seek Dismissal Of Dialysis Price-Fix Suit
• Dexcom Faces Class Action Over Glucose Monitor Tech
• High Court, Not A Single Justice, Should Decide On Recusal
• Trump Unveils IVF Drug Pricing Deal: 'We Want More Babies'
• Generics Makers Urge 3rd Circ. To Nix Price-Fixing Classes
• Jazz Denied Preferred Drug Royalty Rate, But Still Gets Boost
• Bankrupt Rite Aid Trust Sues Walgreens Over Opioid Costs
• Nexus Wants New Trial After Exela Cleared In $89M IP Case
• Bavarian Nordic Gets Sweetened $3.1B Bid But Hurdles Linger
• Traveling Solo Makes Me A Better Lawyer
• Top Del. Judge Details Views On Willful Infringement Issues
• Saudi Arabia Fights $100M Arbitral Award To Qatar Pharma
• Ga. Justices Revive Suit Over L'Oréal Hair Relaxer Health Risks
• Chancery 'Rewrote' $3.4B Merger Deal, J&J Tells Del. Justices
• Consumer Says Nail Fungus Product Falsely Marketed
• Latest PTAB Moves Suggest A Subtle Recalibration
• DOJ's Tracing Rule For Pandemic Loan Fraud Is Untenable
• Geico Says Cos. Owe $415K For Fraudulent Med Gear Scheme
• Del. Ruling Reaffirms High Bar To Plead Minority Control
• Greenberg Traurig Lands Wilson Sonsini Life Sciences Pro
• Some Federal Workers Win Quick Block On Shutdown Layoffs
• Law School's Missed Lessons: Client Service
• NJ, Del. Judges Stress Value Of Local Counsel For IP Attys
• Skinny Labels, Orange Book Take Center Stage In IP Talks
• Full 3rd Circ. Won't Rethink $45M CareDx False Ad Case
• Relief Concerns Grow As Sectoral Tariff Actions Build
• Embryo Loss Class Claims Hinge On Calif. Suit, Judge Says
• 6th Circ. Won't Revive Allergy Tester's Antitrust Case
• How Occasional Activists Have Reshaped Proxy Fights
• Meet HHS General Counsel Michael Stuart
• Attempts To Revive Stroke Treatment Patents Fail At Fed. Circ.
• Freshfields Guides J&J's Planned Orthopedics Unit Spinoff
• Ōura Valuation Soars To $11B After $900M Financing Round
• Catching Up With Delaware's Chancery Court
• Blood Test Co. Can't Escape Willful Infringement Claims
• Covington, Sidley Guide $700M BioCryst Allergic Disease Deal
• High Court Won't Hear FDA Stem Cell Regulation Fight
• Some Cases Advance In Latest Stewart Discretionary Rulings
• Zantac MDL Suits Were Impropely Tossed, 11th Circ. Told
• Federal Worker Unions Press For Immediate Block Of Layoffs
• AstraZeneca Strikes 'Most Favored Nation' Price Deal
• ATyr Pharma Faces Investor Suit Over Failed Drug Trial
• What To Expect After FDA Warnings To GLP-1 Compounders
• Where 4th And 9th Circ. Diverge On Trade Secret Timing
• Profs Say Apple Used Copyrighted Material For AI Training
• Covington, Goodwin Guide Bristol Myers' $1.5B Orbital Buy
• Pharma Co. Escapes Suit Over Ex-CEO's Alleged Misconduct
• Clinical Trial Co. Settles Severance Fight With Ex-VP
• UK Litigation Roundup: Here's What You Missed In London
• Adapting To Private Practice: 3 Tips On Finding The Right Job
• Justices Urged To Clarify Patent Validity In Entresto Case
• Biotronik Wants Full 9th Circ. Review Of Whistleblower Ruling
• Pharma Co. Looks To Nix 'Absurd' Award Over Acne Drug
• 9th Circ. Probes Buyers On HIV Drug Antitrust Claims
• NJ Justices Probe Insurer's Role In $12M Settlement Fight
• Mich. Justice Eyes Scope Of Judge-As-Grand-Jury Issue
• Judge Axes Cell Analysis Patent In Case Against Parse
• Hemp Co. Asks Del. Court To Defer Ex-Exec's Suit To Australia
• Tivity Health Investors Seek Final OK Of $17M Settlement
• Pet Owner Keeps State, But Not Fed., Elanco Tick Meds Suit
• Patient Asks 4th Circ. To Revive Faulty Ethicon Stapler Suit
• Ropes, Kirkland Guide $5.2B Novo Nordisk Liver Disease Deal
• Munck Wilson Taps Texas Atty To Lead Life Sciences Practice
• Painting Makes Me A Better Lawyer
• Senate IP Leader Plans Push To Pass Patent Eligibility Bill
• ALN Medical Strikes $4M Data Breach Deal With 1.8M Users
• GSK Doesn't Have To Explain COVID Vax Claims For Moderna
• Del. Judge May Have Mallinckrodt Choose: Injunction Or $10M
• Power Cos. Want In On Challenge To W.Va. Regional Haze Plan
• Courts Are Still Grappling With McDonnell, 9 Years Later
• Jackson Walker Gets Healthcare Atty From Sheppard Mullin
• Ex-Teva Counsel Joins Moore & Van Allen's IP Team
• Conn. High Court OKs DNA Taken From Trash Sans Warrant
• Minn. 'Sober Home' Companies Sued After Tenant Killed 2
• Fed. Circ. Focuses On Breadth Of UPenn IP In Eligibility Fight
• Alto Neuroscience Execs Sued Over Rosy Drug Claims
• Bausch And Teva Blocked Cheaper IBS Drug, Retailers Say
• 9th Circ. Revives Ex-Service Members' Antimalarial Drug Suit
• Emisphere Shareholder Wants Out Of $32M Class Settlement
• Biogen Says Investors Can't Expand Alzheimer's Drug Suit
• Drug Tax Outdoes Biblical Punishment, 5th Circ. Judge Says
• DC Circ. Denies Biotech Co.'s Nasdaq Delisting Appeal
• Biote Sues In Del. To Block Founder Indemnification Suit
• AGs Rip DOJ Bid To Pause Planned Parenthood Funding Suit
• 3rd Circ. Won't Rehear J&J Investor Cert. Appeal
• J&J Hit With $966M Verdict In Calif. Talc Lung Cancer Case
• La. Challenges Mail-Order Access To Abortion Medication
• Holland & Knight Adds Ex-EPA GC As Team Co-Chair In DC
• AI Will Transform Patent Examination For The Better
• Ex-Sprinter Gets 18 Mos. For Doping Scheme, COVID-19 Fraud
• Hybrid Claims In Antitrust Disputes Spark Coverage Battles
• Justices Pressed To Overturn TM Denial Of Dark Green Gloves
• Fed. Circ. Examines $41.8M Seagen Cancer Drug Patent Case
• Supplement Co. Sold Soviet-Era Drug As Sleep Aid, Suit Says
• Drug Ad Crackdown Demonstrates Admin's Aggressive Stance
• Fed. Circ. Vacates J&J's $20M Loss Over Patent Ownership
• Gilead Gets HIV Generic Drugs Barred From Market Until 2036
• 2 Firms To Lead Humana Investor Suit Over Post-COVID Costs
• Neuriva 'Brain Health' Products Don't Work, Class Suit Claims
• Law Profs Say CareDx False Ad Verdict Should Stand
• 3rd Circ. Rejects Novo Nordisk's Medicare Pricing Challenge
• Hagens Berman Fights Sanctions Over Thalidomide Suits
• Protecting Sensitive Court Filings After Recent Cyber Breach
• Cooley Adds Life Sciences Trio From WilmerHale, Sidley
• High Court Turns Down 6 Patent Cases At Start Of Term
• Justices Won't Review Blacklisting Case Against LegitScript
• Up First At High Court: Election Laws & Conversion Therapy
• 4 Top Supreme Court Cases To Watch This Term
• Few Petitions Move Forward In Newest Discretion Reviews
• 6th Circ. Will Hear Ohio PBM Fight Arguments In December
• Zynex Investors Seek To Merge, Stay Insider Trading Suits
• NIH Sets Patent License Policy Aimed At Promoting Access
• 2nd Circ. Erases Injunction In Pet Supplement False Ad Fight
• Benzene At NC BASF Plant Caused Cancer, Ex-Worker Says
• The Roberts Court At 20: How The Chief Is Reshaping America
• Stryker Gets Fed. Circ. To Ax Bone Fusion Patent Claims
• PTAB Condemns Bristol-Myers' 'Whac-A-Mole Strategy'
• FDA OKs New Generic Abortion Pill, Drawing Conservative Ire
• Feds Eye Partial Pretrial Ruling In Regeneron FCA Case
• NC Chief Judge Scolds Medical Supply Co.'s 'Rude' Demand
• Peach State Panel Tosses $500K Verdict In Peach Picking Spat
• AstraZeneca Asks Judge To Block Colorado's 340B Drug Law
• Bain Inside Trade Claims Advance In Del. Cerevel Sale Suit
• NC State Demands Monsanto Pay For 'Toxic' PCB Cleanup
• Fed. Circ. Affirms Cutting $10M Med Device IP Verdict To $1
• Many Cos. Not Ready For National Security Risks, Report Says
• J&J Must Pay $10M In Punitive Damages After Asbestos Loss
• Singaporean Biotech To Go Public Via $1.5B SPAC Merger
• Court Warned Of Harm From Delaying Medical Device Merger
• Judging Figure Skating Makes Me A Better Lawyer
• Squires Jumps Right Into Patent Eligibility Reform
• Eli Lilly's Drug Suit Slammed As 'Anti-Competitive' Move
• EPA Seeks Dismissal Of Flint Bellwethers, Says It's Not Liable
• Inventor's $11M Award Slashed To $5M Over Pet Device IP
• Medtronic Knocks Out Investor Suit Over Insulin Pump Issues
• Monthly Merger Review Snapshot
• Texas Judge Sends Mifepristone Challenge To Missouri Court
• Trending At The PTAB: Petitioners' Settled Expectations
• Ga. Atty DQ'd From 'Extremely Weird' Pharma Fraud Case
• 9th Circ. Ruling May Help Pharma Cos. Avert Investor Claims
• What Ethics Rules Say On Atty Discipline For Online Speech
• Cozen O'Connor Adds Healthcare Litigator To Philly Office
• Weil, Morgan Lewis Steer Up To $900M Biopharma Purchase